 | Up a level |
Pericàs, Juan M; Anstee, Quentin M; Augustin, Salvador; Bataller, Ramón; Berzigotti, Annalisa; Ciudin, Andreea; Francque, Sven; Abraldes, Juan G; Hernández-Gea, Virginia; Pons, Mònica; Reiberger, Thomas; Rowe, Ian A; Rydqvist, Peter; Schabel, Elmer; Tacke, Frank; Tsochatzis, Emmanuel A; Genescà, Joan (2024). Author Correction: A roadmap for clinical trials in MASH-related compensated cirrhosis. (In Press). Nature reviews Springer Nature 10.1038/s41575-024-00976-3
Pericàs, Juan M; Anstee, Quentin M; Augustin, Salvador; Bataller, Ramón; Berzigotti, Annalisa; Ciudin, Andreea; Francque, Sven; Abraldes, Juan G; Hernández-Gea, Virginia; Pons, Mònica; Reiberger, Thomas; Rowe, Ian A; Rydqvist, Peter; Schabel, Elmer; Tacke, Frank; Tsochatzis, Emmanuel A; Genescà, Joan (2024). A roadmap for clinical trials in MASH-related compensated cirrhosis. (In Press). Nature reviews Springer Nature 10.1038/s41575-024-00955-8
Reiberger, Thomas; Berzigotti, Annalisa; Trebicka, Jonel; Ertle, Judith; Gashaw, Isabella; Swallow, Ros; Tomisser, Andrea (2023). The rationale and study design of two phase II trials examining the effects of BI 685,509, a soluble guanylyl cyclase activator, on clinically significant portal hypertension in patients with compensated cirrhosis. Trials, 24(1), p. 293. BioMed Central 10.1186/s13063-023-07291-3
